Previous studies had indicated a positive correlation of FAT1 mutation with the durable clinical benefit of ICB in non-small cell lung cancer (Fang et al. 2019, Feng et al. 2022). The gene discussed is FAT1; the disease is non-small cell lung carcinoma.